Abstract
Orthobunyaviruses (family Peribunyaviridae) represent one of the most diverse groups of arboviruses, infecting humans, livestock, and wildlife worldwide. Despite their broad geographic distribution and ecological complexity, most orthobunyaviruses remain poorly characterized, with limited understanding of their genomic diversity, transmission dynamics, and pathogenic potential. While research has focused on clinically recognized viruses such as Oropouche virus (OROV), La Crosse virus (LACV), Jamestown Canyon virus (JCV), and Schmallenberg virus (SBV), numerous neglected lineages like Ilesha virus (ILEV), Bwamba virus (BWAV), and Ingwavuma virus (INGV) continue to circulate silently, particularly in Africa, Asia, and Latin America. Recent outbreaks of OROV in South America and the emergence of SBV in Europe highlight their capacity for rapid spread and significant public and animal health impact. The segmented negative-sense RNA genome of orthobunyaviruses enables reassortment, a key evolutionary mechanism that drives diversification and may generate strains with altered virulence or host range. In addition, climate change, environmental disruption, and increased human-animal-vector interactions may facilitate expansion into new regions. This review synthesizes current knowledge on taxonomy, evolution, ecology, clinical features, diagnostics, and surveillance strategies. We emphasize the importance of integrated genomic monitoring and One Health approaches to strengthen preparedness against emerging and neglected orthobunyaviruses.
Keywords: Orthobunyaviruses, Arbovirus, Emerging infectious diseases, Genomic surveillance -Vector-borne diseases, Zoonoses, Public health, One Health
Introduction
Orthobunyaviruses (family Peribunyaviridae) constitute one of the most diverse groups of arboviruses, infecting a wide range of vertebrate hosts, and are transmitted primarily by mosquitoes and biting midges. Despite this diversity, the majority of orthobunyaviruses remain poorly characterized, with limited data on their geographical distribution, host range, pathogenic potential, and transmission dynamics. Historically, research efforts have focused on a relatively small subset of clinically recognized viruses, whereas many others likely persist in enzootic cycles with limited detection.
Several Orthobunyaviruses have demonstrated the capacity to cause significant human and animal disease, including febrile illness, neuroinvasive syndromes, congenital malformations and major economic losses in livestock [1–3].
Recent outbreaks caused by Oropouche virus (OROV) in South America, the continued circulation of Schmallenberg virus (SBV) in Europe, and the persistent burden of La Crosse virus (LACV) in the United States highlight the capacity of orthobunyaviruses to emerge or re-emerge and affect both human and animal health [4]. These events also illustrate how orthobunyaviruses thrive at the intersection of humans, animals, vectors, and dynamic environments shaped by ecological disruption, climate change and global mobility. Their segmented RNA (ribonucleic acid) genomes facilitate genetic reassortment, increasing the likelihood of variants with altered host range or virulence [5, 6].
Well-characterized orthobunyaviruses demonstrate the substantial public health and veterinary burden associated with this diverse viral group. OROV, first identified in the mid-twentieth century, has evolved into a major public health concern in Central and South America, with recurrent urban outbreaks of acute febrile illness and increasing international attention [7, 8]. Its association with neuroinvasive disease and possible congenital complications, together with the growing number of confirmed cases reported in recent years, underscores its expanding clinical and epidemiological relevance [3, 9]. In North America and Europe, orthobunyaviruses such as LACV, SBV, Jamestown Canyon virus (JCV), and Akabane virus (AKAV) are associated with pediatric encephalitis, febrile illness, neuroinvasive syndromes, congenital malformations, and reproductive losses, resulting in significant morbidity and economic impact [10–12].
However, despite their apparent ubiquity, many orthobunyaviruses remain neglected, under-characterized, and are largely absent from routine surveillance, even though they circulate broadly in Africa and other tropical regions [13]. Viruses such as Ilesha virus (ILEV), Bwamba virus (BWAV), Ingwavuma virus (INGV), Sabo virus, and several Simbu-serogroup members have been intermittently detected in humans, livestock, or vectors, yet their ecology, genetic diversity, and pathogenic potential remain poorly understood [13]. Indeed, BWAV and ILEV have been historically linked to febrile illness, while recent studies reveal hidden diversity in Simbu-serogroup viruses, suggesting additional cryptic species may circulate undetected [13–15].
In the context of climate change, ecosystem disruption, and intensified human-animal-vector interactions, orthobunyaviruses represent an increasing yet underestimated threat.
This review synthesizes current knowledge on orthobunyavirus taxonomy, evolution, ecology, clinical relevance, diagnostic challenges, and surveillance strategies, with particular emphasis on the need for integrated One Health approaches to improve preparedness, early detection and risk assessment.
Review scope and methodology
This narrative review is based on a structured analysis of peer-reviewed literature on orthobunyaviruses published between 2001 and 2025, complemented by selected earlier landmark studies when directly relevant to taxonomy, reassortment history, or vector biology. Publications were identified through searches in PubMed, Web of Science, and Google Scholar using combinations of the keywords “Orthobunyavirus”, “Peribunyaviridae”, “arbovirus”, “One Health”, “genomic surveillance”, and names of specific viruses.
The inclusion criteria comprised original research articles, reviews, and surveillance reports focusing on orthobunyaviruses, their molecular biology, epidemiology, ecology, and clinical impact. Studies were included if they provided relevant data on virus characterization, transmission dynamics, host-vector interactions, or public health implications. Articles not directly related to orthobunyaviruses or lacking sufficient methodological detail were excluded.
The screening process was conducted in two stages: an initial screening of titles and abstracts to assess relevance, followed by full-text review of selected articles. Reference lists of included studies were also screened to identify additional relevant publications.
Additional data were retrieved from authoritatives sources, including reports from the International Committee on Taxonomy of Viruses (ICTV), as well as surveillance documents from the WHO/PAHO (World Health Organization / Pan American Health Organization) and the CDC (Centers for Disease Control and prevention). These sources were selected due to their recognized expertise and reliability in virology, taxonomy, and global health surveillance.
The review integrates virological, ecological, clinical, and epidemiological evidence within a One Health framework to identify knowledge gaps, emerging risks, and research priorities.
Taxonomy, genomics, and evolutionary dynamics
Orthobunyaviruses are classified within the order Elliovirales, family Peribunyaviridae, and genus Orthobunyavirus which encompasses a diverse group of tri-segmented negative-sense RNA viruses [16]. According to ICTV taxonomy, the genus Orthobunyavirus comprises multiple formally recognized virus species. Each virus species is a taxonomic unit defined on the basis of genetic and evolutionary criteria and may include one or more distinct viruses (i.e., virus names used in surveillance and outbreak reporting, such as Oropouche virus or Bunyamwera virus). In this framework, virus names refer to the actual circulating or detected viral entities (e.g., Oropouche virus), whereas species names represent ICTV-defined taxonomic groups that may encompass genetically related viruses. The genus Orthobunyavirus therefore represents a higher-level taxonomic category that includes all orthobunyavirus species. In addition to ICTV-defined taxonomy, orthobunyaviruses have historically been organized into serogroups (e.g., Simbu, California, Bunyamwera, Bwamba, and Tete groups), based on antigenic cross-reactivity patterns. These serogroups are useful for epidemiological and serological classification but do not constitute official ICTV taxonomic ranks and may not always align with phylogenetically defined species boundaries. Recent taxonomic updates rely on molecular phylogeny rather than serology alone, reflecting the growing contribution of genomic data to virus classification [17].
The genome comprises three negative-sense RNA segments: L, M and S (Fig. 1). The L segment encodes the RNA-dependent RNA polymerase; the M segment encodes the Gn and Gc envelope glycoproteins and, in many viruses, NSm; and the S segment encodes the nucleocapsid protein N and may also encode NSs. NSs is an antagonist of host antiviral responses and an important virulence determinant in several, but not all, orthobunyaviruses [6, 16–18].
Fig. 1.

Orthobunyavirus virion structure, genome organization, and major protein functions. (A) Virion structure: Enveloped particles display Gn and Gc glycoprotein spikes and contain three internal ribonucleoprotein complexes corresponding to the L, M, and S negative-sense RNA segments. (B) Genome organization: The L segment encodes the RNA-dependent RNA polymerase, the M segment encodes the Gn–NSm–Gc polyprotein, and the S segment encodes the nucleocapsid protein N and, in many orthobunyaviruses, NSs. Conserved complementary terminal sequences support transcription and replication. (C) Major protein products and functions: L mediates transcription and genome replication; Gn and Gc mediate attachment, entry, and membrane fusion; N encapsulates viral RNA; NSm contributes to assembly and infection in arthropod vectors; and NSs antagonizes host antiviral responses. Genome segmentation enables reassortment during co-infection
Orthobunyaviruses evolve through both mutation and reassortment. Reassortment represents an important mechanism of orthobunyavirus evolution because co-infecting viruses may exchange complete genome segments, generating progeny with altered genetic and potentially phenotypic characteristics [19]. A well-documented example is Ngari virus, a natural reassortant containing L and S segments related to Bunyamwera virus and an M segment related to Batai virus. During the 1997–1998 hemorrhagic fever outbreak in Kenya and Somalia, isolates initially referred to as Garissa virus were subsequently identified as Ngari virus, which was associated with severe and fatal human disease [20, 21]. Reassortment has also been documented among members of the Simbu serogroup and may contribute to their genetic diversity and emergence; however, its direct effects on virulence, host range, or transmission require virus-specific experimental evidence [6, 22, 23].
From a One Health perspective, reassortment represents a central mechanism underpinning the emergence and diversification of orthobunyaviruses across interconnected human, animal, and environmental systems. Well-characterized orthobunyaviruses, such as OROV, LACV, and members of the Simbu serogroup, have demonstrated that co-circulation in shared ecological niches involving arthropod vectors, vertebrate hosts, and reservoir species facilitates frequent genome segment exchange. These reassortment events can generate novel viral species with altered virulence, host range, or transmission efficiency, sometimes resulting in significant outbreaks in humans or livestock. In contrast, the majority of orthobunyaviruses circulating in endemic regions remain poorly characterized, with limited genomic, ecological, and epidemiological data [13].
Many neglected viruses, particularly those identified in Africa and parts of Asia, are known only from historical isolations or partial genome sequences, and their reservoir hosts, vector associations, and pathogenic potential remain largely undefined (Table 1). More detailed information on the date and location of first detection, reported geographic distribution, associated arthropod species, vertebrate hosts, and supporting references is provided in Supplementary Table S1.
Table 1.
Selected neglected and emerging orthobunyaviruses: distribution, ecological evidence, clinical attribution and knowledge gaps. Evidence note: “arthropod evidence” includes field detection or isolation and must not be interpreted as proof of vector competence unless experimental transmission has been demonstrated. “Clinical evidence” distinguishes confirmed or outbreak-supported attribution from limited temporal, serologic or phylogenetic association. [5, 13–15, 19, 20, 23, 25, 53]
| Virus | First detection and reported distribution | Arthropod evidence | Vertebrate evidence | Clinical evidence | Genome status | Priority gaps |
|---|---|---|---|---|---|---|
| Ilesha virus | Nigeria, 1957; West/Central Africa and Madagascar | Field isolation from Anopheles gambiae; competence not demonstrated | Human isolates and serologic evidence | Historical hemorrhagic fever and meningoencephalitis reports; contemporary burden uncertain | Three-segment data available for archived strains | Prospective case finding; differential diagnosis; experimental vector studies |
| Bwamba virus | Uganda, 1937; Uganda, Tanzania, Central Africa; wider serologic evidence | Field isolates from An. gambiae and An. funestus; competence not demonstrated | Human infection documented | Acute Bwamba fever with headache, rash, arthralgia and occasional meningeal signs | Three-segment data available | Current incidence, diagnostic specificity and vector competence |
| Ingwavuma virus | South Africa, 1960s; southern Africa and South/Southeast Asia | Bird and mosquito isolates; experimental competence shown for selected mosquito species | Birds, pigs and a limited number of human infections | Febrile human infection reported; clinical spectrum poorly defined | Three-segment data available | Human burden, reservoir contribution and field transmission efficiency |
| Simbu virus | Nigeria, 1960s; Africa and Middle East | Mosquito/midge isolation; competence incompletely defined | Serologic/field evidence in ruminants | Disease attribution to Simbu virus itself is not established; effects of other Simbu-serogroup viruses should not be extrapolated | Three-segment data available | Virus-specific pathology, host range and transmission studies |
| Sango virus | Nigeria, 1960s; Nigeria and Israel | Historical Culicoides isolation; competence not established | Isolated from symptomatic cattle in Israel | Temporal association with bovine illness; causality remains limited | Sequence data available; some strain datasets incomplete | Controlled infection, vector competence and broader livestock surveillance |
| Sabo virus | Nigeria, 1966; Nigeria and Central Africa | No confirmed vector; historical goat-blood isolation | Goat isolate | No confirmed disease association | Three-segment data available | Vector, reservoir, pathogenicity and geographic distribution |
| M’Poko virus | Central African Republic, 1966; Central Africa and Senegal | Field isolates from Culex spp.; competence not established | No well-defined vertebrate host | No confirmed disease association | Three-segment data available | Host range, vector competence and clinical surveillance |
| Botambi virus | Central African Republic, 1960s; Central/West Africa | Field isolation from Culex guiarti; competence not established | No well-defined vertebrate host | No confirmed disease association | Three-segment data available | Contemporary circulation, host range and pathogenicity |
| Tanga virus | Tanzania, 1962; East/West Africa | Field isolation from Anopheles funestus; competence not established | No well-defined vertebrate host | No confirmed disease association | Segment data available; completeness varies by strain | Complete genomes, host range, competence and clinical relevance |
| Ngari virus | Senegal, 1993; multiple African countries | Mosquito-associated; field isolates reported | Humans and livestock | Severe febrile and hemorrhagic disease; outbreak-associated evidence | Complete L/M/S genomes define a Bunyamwera–Batai reassortant | Routine differential diagnosis, vector ecology and animal–human interface |
Given the demonstrated capacity for reassortment among better-studied orthobunyaviruses, the silent circulation of these understudied viruses raises concern that similar evolutionary processes may be occurring undetected.
Phylogenetic analyses reveal that orthobunyaviruses represent a highly diverse and complex evolutionary group, with many lineages still poorly characterized. Traditional classification based on serology has often led to misclassification, especially among closely related viruses or when only partial genomic data are available. For example, viruses isolated from mosquitoes in Bandia, Senegal, in 1969, were initially classified as ILEV but were later identified as Batai virus through molecular characterization [24].
Several neglected orthobunyaviruses, including ILEV, BWAV, INGV, and Sabo virus, cluster phylogenetically with established human or animal pathogens, suggesting that they may share similar emergence potential under changing ecological and epidemiological conditions [13]. These observations highlight the need for comprehensive genomic surveillance to clarify orthobunyavirus diversity, detect reassortment events, and identify lineages relevant to human and animal health.
Figure 2 summarizes relationships among host range, clinical manifestations, virus diversity, and vector associations across orthobunyaviruses, emphasizing the mismatch between the number of circulating viruses and the evidence available for most of them. Orthobunyaviruses are linked to a broad spectrum of outcomes in humans and livestock, including febrile illness, neuroinvasive disease, hemorrhagic fevers, abortions, stillbirths, teratogenic effects, congenital malformations, and meningoencephalitis [6, 25]. The figure distinguishes well-studied orthobunyaviruses (blue), for which epidemiological and clinical links are relatively well established, from neglected orthobunyaviruses (yellow), which are connected to similar clinical and ecological patterns but remain far less characterized.
Fig. 2.

Evidence matrix summarizing the ecological and clinical associations of well-studied and neglected orthobunyaviruses. Rows represent individual orthobunyaviruses, whereas columns represent arthropod vectors, vertebrate hosts, and clinical manifestations. Blue circles indicate established or documented associations. Teal diamonds indicate associations supported by field isolation, virus detection, or serological evidence, which do not independently demonstrate vector competence or disease causation. Open amber circles marked “L” indicate historical or limited attribution, and gray squares indicate unresolved or unconfirmed associations. Blank cells indicate that an association was not reported in the evaluated sources. The stacked bars above the matrix show the number of orthobunyaviruses assigned to each evidence category for each variable. Associations involving neglected orthobunyaviruses should be interpreted cautiously and highlight important knowledge gaps requiring further virological, epidemiological, ecological, and experimental investigation
It also illustrates the ecological complexity of these viruses, with mosquitoes and midges as key vectors and birds and ruminants as potential animal hosts or reservoirs. By linking human and livestock disease to transmission ecology, Fig. 2 underscores the One Health importance of orthobunyaviruses and suggests that neglected members of this group may contribute to underrecognized febrile, neurological, hemorrhagic, and reproductive syndromes, particularly in settings with limited diagnostic capacity. Overall, the figure provides a hypothesis-generating framework that identifies key gaps in host range, vector competence, and clinical attribution, and supports the need for integrated surveillance and targeted experimental studies to clarify the public health and veterinary significance of neglected orthobunyaviruses.
Ecology, transmission, and vector-host interactions
The ecology of orthobunyavirus transmission involves complex interactions among viruses, arthropod vectors, vertebrate hosts, and environmental conditions.
Mosquitoes and Culicoides biting midges are the principal arthropods associated with orthobunyavirus transmission. However, detection of viral RNA, antigen, or infectious virus in field-collected arthropods does not, by itself, demonstrate vector competence. Such findings establish an ecological association or natural infection, whereas vector competence refers to the intrinsic ability of an arthropod to acquire a virus, support its replication and dissemination, and transmit infectious virus to a susceptible host [26, 27, 28]. For well-characterized orthobunyaviruses, including LACV, JCV, SBV, and AKAV, vector attribution is supported by combinations of field, epidemiological, and experimental evidence [23, 26–30]. In contrast, many arthropod associations reported for neglected orthobunyaviruses are based primarily on historical virus isolation or molecular detection and should therefore be regarded as suspected or putative until confirmed through experimental vector-competence and transmission studies [13].
Transovarial transmission in mosquitoes can contribute to viral maintenance between outbreak periods and may support overwintering in some ecological settings, although the strength of evidence varies depending on the virus-vector system. Vertebrate hosts include humans, domestic animals, and wildlife, with humans often acting as incidental hosts [7, 27]. Domestic ruminants are primary hosts for several veterinary-relevant orthobunyaviruses, in which infections can lead to abortions, stillbirths, and congenital malformations [23, 30].
Environmental and anthropogenic factors, such as climate change, deforestation, agricultural expansion, urbanization, livestock intensification, and global mobility, shape orthobunyaviruses transmission by affecting vector abundance, vector activity, and opportunities for host-vector contact [6, 31]. These ecological dynamics reinforce the need for an integrated One Health approach that incorporates vector ecology, host diversity, and environmental change to better understand, predict, and anticipate the emergence of Orthobunyaviruses.
Emerging orthobunyaviruses of public health concern
Although many Orthobunyaviruses remain neglected, several have emerged as significant threats to human and animal health. OROV, historically associated with and endemic to the Amazon Basin, has been identified as the cause of large outbreaks in endemic and newly affected areas in South America and the Caribbean since late 2023 [32, 33]. In 2025, 12,786 confirmed cases were reported, with most in Brazil (11,888), followed by Panama (501) and Peru (330); imported cases were reported in Uruguay (3), Chile (2), Canada (1), and the United States (1) [34], highlighting its expanding geographic footprint and public health relevance beyond its traditional range.
In North America, LACV and JCV are mosquito-borne Orthobunyaviruses associated with febrile illness and neurological disease, including encephalitis [35, 36].
In North America, LACV is an important cause of pediatric arboviral neuroinvasive disease in the United States, although annual counts vary by year and surveillance intensity [27, 37]. JCV is also likely underdiagnosed due to often mild or non-specific symptoms [29]. The CDC ArboNET data has reported increased recognition of JCV cases in recent years. Between 2012 and 2021, 267 cases were reported, primarily in Wisconsin and Minnesota, with 32 cases recorded in 2021 alone [38]. As of 14 July 2026, the CDC listed 22 JCV disease cases for 2025, including 14 neuroinvasive cases, while noting that these data remain preliminary and subject to change [39].
Other neglected yet epidemiologically relevant Orthobunyaviruses include Inkoo virus (INKV), ILEV, BWAV, and INGV which have been detected in humans, animals, or vectors, but remain poorly understood regarding their ecology, transmission, and pathogenic potential. First isolated in 1964 from Aedes communis in Inkoo, Finland, INKV is among the mosquito-borne viruses associated with human infection in Europe [40].
In livestock, SBV and AKAV are among the most consequential Orthobunyaviruses. Both viruses belong to Simbu serogroup and infect ruminants such as sheep, cattle, and goats. Although they are not direct human pathogens, their impact on food security, agricultural livelihoods, and economic stability in endemic regions makes them relevant to human health [26]. Outbreaks can disrupt livestock production, increase veterinary costs, and impose socio-economic burdens, particularly in communities highly dependent on ruminant farming. SBV and AKAV therefore illustrate how animal health shocks can translate into broader societal impacts through interconnected animal-human-environment systems.
Clinical manifestations and diagnostic challenges
Orthobunyaviruses cause a wide spectrum of disease in humans and animals. In humans, infections may present as an acute febrile illness or progress to neurological involvement, including central nervous system disease [41]. In ruminants, particularly those infected with Simbu serogroup viruses, disease can result in congenital malformations and reproductive losses, generating substantial livestock health and economic impacts [41]. Because clinical manifestations are often non-specific and overlap with other endemic infections, orthobunyavirus disease is likely under-recognized and under-reported, especially in settings with limited laboratory capacity.
Diagnostic capacity remains constrained by technical and practical barriers. Molecular detection through RT-PCR (reverse-transcription polymerase chain reaction) is sensitive but depends on appropriate timing of sample collection and access to specialized laboratory infrastructure, limiting its utility in many endemic regions. Diagnostic testing should therefore be guided by the clinical syndrome and the interval since symptom onset. In patients with acute febrile illness, serum or plasma collected during the first week of illness is generally the preferred specimen for RT-PCR, when viremia is expected to be highest [33]. Molecular sensitivity subsequently decreases as viremia declines; therefore, a negative RT-PCR result from a specimen collected late in the clinical course does not exclude infection [33]. In suspected neuroinvasive disease, cerebrospinal fluid (CSF) and serum should be collected concurrently. Although RT-PCR can be performed on CSF, viral RNA is often no longer detectable when neurological symptoms develop, making virus-specific IgM (Immunoglobulin M) testing in CSF and serum particularly important [33, 42, 43].
Serological testing is further complicated by cross-reactivity among closely related orthobunyaviruses, hindering species-level identification in areas where multiple viruses co-circulate. Positive IgM results should therefore be confirmed, where available, using plaque-reduction neutralization testing (PRNT). Whenever possible, paired acute- and convalescent-phase serum samples should be collected, generally at least 10–14 days apart, to demonstrate seroconversion or a fourfold or greater increase in neutralizing-antibody titers [33, 42, 43]. However, even neutralization assays may not fully distinguish closely related viruses, and results should be interpreted together with clinical, epidemiological, and molecular findings [44]. Expanding RT-PCR capabilities to subnational laboratories remains a critical yet challenging goal that could strengthen early detection [45].
Veterinary diagnosis requires a syndrome-specific approach that differs from the testing strategy used for human infection.
For suspected orthobunyavirus infection in animals, diagnostic testing should be adapted to the clinical presentation and stage of infection. During acute infection, EDTA (Ethylenediaminetetraacetic acid) whole blood, serum, or plasma may be tested by RT-PCR, although the short duration of viremia can limit molecular detection. In cases of abortion, stillbirth, or congenital malformations, fetal central nervous system tissues, particularly brain and spinal cord, together with placenta and other available fetal tissues should be prioritized for molecular testing and pathological examination [26, 46,47]. Serological approaches include indirect or competitive ELISA (Enzyme-Linked Immunosorbent Assay) and virus-neutralization tests, with neutralization providing greater specificity when antigenically related Simbu-serogroup viruses co-circulate [12, 15, 48]. Commercial ELISA kits have been validated for selected viruses, particularly SBV, but equivalent assays are not uniformly available for all veterinary orthobunyaviruses, and their performance may vary according to the virus, animal species, and epidemiological setting [46, 48, 49].
Metagenomic sequencing offers a powerful, hypothesis-free approach for identifying known and neglected orthobunyaviruses directly from clinical or environmental samples [13]. However, it remains expensive, technically demanding, and generally unavailable outside specialized research laboratories. Untargeted metagenomic sequencing is also generally less sensitive than targeted RT-PCR in low-viremia samples because viral nucleic acids may represent only a very small proportion of the total host and microbial nucleic-acid background [50]. Consequently, a negative metagenomic result does not exclude infection. Amplicon-based or hybridization-capture enrichment may improve genome recovery from low-titer specimens, although these approaches require prior sequence information and appropriate validation [51]. Its use has nonetheless led to the discovery of previously unrecognized orthobunyaviruses in unexplained human infections, underscoring its potential utility [52]. In practice, metagenomics is most impactful when embedded in a tiered algorithm: first-line syndromic RT-PCR panels, followed by metagenomics for RT-PCR-negative severe cases, unusual clusters, immunocompromised patients, or suspected reassortant.
Together, these challenges underscore the need for improved and accessible diagnostic tools, including multiplex assays capable of detecting multiple orthobunyaviruses simultaneously and field-adapted point-of-care platforms. A practical diagnostic strategy should combine early molecular testing with serological testing and neutralization assays for patients sampled later in the course of illness or presenting with neuroinvasive disease. The recommended specimens, testing windows, and interpretation of results are summarized in Table 2. Strengthening diagnostic capacity is essential for accurate burden estimation, timely outbreak detection, and integrated One Health surveillance across human and animal populations.
Table 2.
Practical diagnostic approach to suspected human orthobunyavirus infection
| Clinical context and timing | Recommended specimens | Initial testing | Confirmation and interpretation |
|---|---|---|---|
| Acute febrile illness, generally ≤ 7 days after onset | Serum or plasma | Virus-specific or syndromic RT-PCR | A positive result confirms acute infection. A late negative result does not exclude infection. |
| Illness > 7 days or negative acute-phase RT-PCR | Acute and convalescent serum | Virus-specific IgM, followed by PRNT | Seroconversion or a ≥ 4-fold rise in neutralizing-antibody titre supports recent infection. |
| Meningitis, encephalitis, or other neuroinvasive disease | CSF and serum collected concurrently | CSF and serum IgM; RT-PCR on CSF and serum where appropriate | CSF IgM may be more informative than RT-PCR. Confirm positive serology by PRNT and interpret with epidemiological findings. |
| Severe unexplained disease, immunocompromised patient, unusual cluster, or suspected reassortant | Syndrome-appropriate specimens, including serum, plasma, CSF, or tissue | Targeted testing first; metagenomic sequencing when initial tests are unrevealing | Confirm metagenomic findings by specific RT-PCR, serology, sequencing, or virus isolation. A negative metagenomic result does not exclude low-level infection. |
Discussion
Orthobunyaviruses represent a genetically diverse and evolutionarily dynamic group of arboviruses with demonstrated impact on both human and animal health [6]. The resurgence of OROV across the Americas since late 2023 illustrates their capacity to re-emerge at scale and expand rapidly beyond historically affected areas [7, 32, 34].
While OROV, LACV, JCV, and SBV have been comparatively well characterized because of their clinical and outbreak significance [7, 23, 37, 53], most orthobunyavirus lineages remain poorly studied.
Their segmented RNA genome enables reassortment, potentially generating viruses with altered biological properties. Evidence from genome-scale datasets and targeted phylogenetic studies demonstrates that natural reassortment is widespread within the group and supports routine sequencing of all three genome segments L, M, and S rather than reliance on partial-genome characterization [6, 54–57]. Major gaps nevertheless persist in genomic coverage, ecological characterization, and taxonomic assignment, particularly for viruses circulating in Africa and Asia, and for historical isolates originally classified using serological methods [13, 24, 58–62].
Recommendations
Based on the major knowledge and surveillance gaps identified in this review, six priority areas should guide future orthobunyavirus preparedness and response within an integrated One Health framework.
Genomic surveillance.
Routine complete-genome sequencing of the L, M, and S segments should be expanded to improve taxonomic assignment, identify emerging lineages, and detect reassortment events. Priority should be given to neglected viruses, historical isolates, severe unexplained infections, unusual outbreaks, and regions with limited genomic representation [6, 13, 24, 52–54].
Vector surveillance and competence studies.
Longitudinal surveillance of mosquitoes and Culicoides biting midges should integrate virus detection with information on arthropod species, location, seasonality, abundance, and host-feeding patterns. Virus detection or isolation from an arthropod should not be considered equivalent to demonstrated vector competence. Suspected vector associations, particularly for neglected viruses, should be evaluated through experimental infection, dissemination, and transmission studies [28, 59].
Clinical diagnostics.
Diagnostic preparedness should use a tiered approach combining RT-PCR during acute infection, paired acute- and convalescent-phase serology, confirmatory neutralization assays, and CSF testing in suspected neuroinvasive disease. Molecular and serological assays capable of differentiating closely related viruses are needed to reduce misclassification caused by antigenic cross-reactivity. Metagenomic sequencing should be prioritized for severe unexplained disease, unusual clusters, immunocompromised patients, and suspected divergent or reassortant viruses, while recognizing its limited sensitivity in low-viremia samples [24, 44–51].
Veterinary surveillance and countermeasures.
Veterinary surveillance should systematically investigate abortions, stillbirths, congenital malformations, reproductive losses, and neurological disease in livestock. These investigations should be linked with vector and genomic surveillance to identify circulating Simbu-serogroup and other veterinary-relevant orthobunyaviruses. Existing vaccines should be evaluated and deployed where appropriate, while vaccine research should be considered for viruses with substantial epidemic, economic, or transboundary potential [23, 26, 46–49].
Data sharing and standardisation.
Complete genome sequences should be deposited rapidly in public databases together with standardized clinical, epidemiological, geographical, host, vector, and sampling metadata. Harmonized nomenclature, genome-based classification, and interoperable data systems are required to support reliable comparisons, reassortment analyses, and real-time risk assessment across countries and regions [16, 17, 54, 58, 61, 62].
Capacity building and regional coordination.
Sustained investments are needed in molecular diagnostics, genomic sequencing, bioinformatics, entomology, veterinary investigation, biobanking, and laboratory quality systems, particularly in under-sampled regions such as Africa and Latin America. Regional networks should support workforce training, reference testing, external quality assessment, reagent access, shared protocols, and coordinated outbreak response [59, 62, 63, 64].
Together, these priorities provide an operational framework for improving the detection, characterization, risk assessment, and control of emerging and neglected orthobunyaviruses across interconnected human, animal, vector, and environmental systems.
Conclusion
Orthobunyaviruses are increasingly important threats to human and animal health, as illustrated by recent OROV outbreaks, neuroinvasive infections, and the substantial reproductive and economic impact of livestock-associated viruses [7, 32, 34, 39]. However, numerous neglected lineages remain insufficiently characterized, particularly regarding their genomic diversity, host range, vector relationships, and pathogenic potential. Consistent nomenclature, complete L/M/S genome characterization, and improved surveillance are therefore essential for detecting emerging lineages and resolving reassortment and taxonomic uncertain [54, 58, 61, 62]. An integrated One Health approach linking clinical, veterinary, vector, genomic, and epidemiological surveillance will be critical to anticipate and mitigate the future emergence of orthobunyaviruses.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
The author would like to gratefully acknowledge all colleagues from Institut Pasteur de Dakar (IPD) especially Dr Ndongo Dia, Head of virology department and Dr Ibrahima Soce Fall, General administrator of IPD.
Abbreviations
- AKAV
Akabane virus
- BWAV
Bwamba virus
- CDC
Centers for Disease Control and Prevention
- CSF
Cerebrospinal fluid
- EDTA
Ethylenediaminetetraacetic acid
- ELISA
Enzyme-Linked Immunosorbent Assay
- Gc
Glycoprotein C
- Gn
Glycoprotein N
- ICTV
International Committee on Taxonomy of Viruses
- IgM
Immunoglobulin M
- ILEV
Ilesha virus
- INGV
Ingwavuma virus
- INKV
Inkoo virus
- JCV
Jamestown Canyon virus
- LACV
La Crosse virus
- NSm
Non-structural protein M
- NSs
Non-structural protein S
- OROV
Oropouche virus
- PAHO
Pan American Health Organization
- PRNT
Plaque-reduction neutralization test
- RdRp
RNA-dependent RNA polymerase
- RNA
Ribonucleic Acid
- RT-PCR
Reverse-transcription polymerase chain reaction
- SBV
Schmallenberg virus
- WHO
World Health Organization
Author contributions
SS and MMD planned and organized the review. SS conducted the literature search and drafted the initial version. NAN and MMD prepared Figs. 1 and 2. SS, NAN, MK and MMD revised and edited the final version of the review.
Funding
No funding was received for this manuscript.
Data availability
No datasets were generated or analysed during the current study.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
All authors consent to publication.
Competing interests
The authors declare no competing interests.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12985-026-03284-1.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Conraths FJ, Peters M, Beer M. Schmallenberg virus, a novel orthobunyavirus infection in ruminants in Europe: potential global impact and preventive measures. N Z Vet J. 2013;61:63–7. 10.1080/00480169.2012.738403. [DOI] [PubMed] [Google Scholar]
- 2.Hughes HR, Kenney JL, Calvert AE. Cache Valley virus: an emerging arbovirus of public and veterinary health importance. J Med Entomol. 2023;60:1230–41. 10.1093/jme/tjad058. [DOI] [PubMed] [Google Scholar]
- 3.Schwartz DA. Novel reassortants of Oropouche virus (OROV) are causing maternal–fetal infection during pregnancy, stillbirth, congenital microcephaly, and malformation syndromes. Genes (Basel). 2025;16:87. 10.3390/genes16010087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Srivastava S, Sah R, Babu MR, Sharma D, Sharma D, Kumar S, et al. The emergence of Oropouche fever: a potential new threat? New Microbes New Infect. 2025;65:101596. 10.1016/j.nmni.2025.101596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Briese T, Bird B, Kapoor V, Nichol ST, Lipkin WI. Batai and Ngari viruses: M segment reassortment and association with severe febrile disease outbreaks in East Africa. J Virol. 2006;80:5627–30. 10.1128/JVI.02448-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Elliott RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014;12:673–85. 10.1038/nrmicro3332. [DOI] [PubMed] [Google Scholar]
- 7.Tilston-Lunel NL. Oropouche virus: an emerging orthobunyavirus. J Gen Virol. 2024;105:002027. 10.1099/jgv.0.002027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Romero-Alvarez D, Escobar LE. Oropouche fever, an emergent disease from the Americas. Microbes Infect. 2018;20:135–46. 10.1016/j.micinf.2017.11.013. [DOI] [PubMed] [Google Scholar]
- 9.Romero-Alvarez D, Manore CA. The foretold Oropouche fever epidemic. Lancet Infect Dis. 2025;25:955–7. 10.1016/S1473-3099(25)00165-3. [DOI] [PubMed] [Google Scholar]
- 10.Ouellette CP. La Crosse virus encephalitis in children. Curr Opin Infect Dis. 2024;37:419–24. 10.1097/QCO.0000000000001042. [DOI] [PubMed] [Google Scholar]
- 11.Dumic I, Nordstrom CW, Patel J, Shweta FNU, Lutwick L. Clinical characteristics and outcome of Jamestown Canyon virus infection in hospitalized Wisconsin patients. Open Forum Infect Dis. 2025;12:ofaf360. 10.1093/ofid/ofaf360. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Selim A, Marzok M, Gattan HS, Hereba AM. A serological study and risk factors associated with Akabane virus infection in cattle in Egypt. Sci Rep. 2025;15:20245. 10.1038/s41598-025-02732-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Sankhe S, Dieng I, Kane M, Diallo A, Ndiaye NA, Top NM, et al. Genomic insights into neglected orthobunyaviruses: molecular characterization and phylogenetic analysis. Viruses. 2025;17:406. 10.3390/v17030406. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Lutwama JJ, Rwaguma EB, Nawanga PL, Mukuye A. Isolations of Bwamba virus from south central Uganda and north eastern Tanzania. Afr Health Sci. 2002;2:24–8. https://pmc.ncbi.nlm.nih.gov/articles/PMC2141559/. [PMC free article] [PubMed] [Google Scholar]
- 15.Oluwayelu D, Wernike K, Adebiyi A, Cadmus S, Beer M. Neutralizing antibodies against Simbu serogroup viruses in cattle and sheep, Nigeria, 2012–2014. BMC Vet Res. 2018;14:277. 10.1186/s12917-018-1605-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.International Committee on Taxonomy of Viruses. Current ICTV taxonomy release: 2025 release (MSL #41). https://ictv.global/taxonomy. Accessed 16 July 2026.
- 17.de Souza WM, Calisher CH, Carrera JP, Hughes HR, Nunes MRT, Russell B, et al. ICTV virus taxonomy profile: Peribunyaviridae 2024. J Gen Virol. 2024;105:002034. 10.1099/jgv.0.002034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Windhaber S, Xin Q, Lozach PY. Orthobunyaviruses: from virus binding to penetration into mammalian host cells. Viruses. 2021;13:872. 10.3390/v13050872. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Gerrard SR, Li L, Barrett AD, Nichol ST. Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol. 2004;78:8922–6. 10.1128/JVI.78.16.8922-8926.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, Muchiri E, et al. An outbreak of Rift Valley fever in northeastern Kenya, 1997–98. Emerg Infect Dis. 2002;8:138–44. 10.3201/eid0802.010023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Bowen MD, Trappier SG, Sanchez AJ, Meyer RF, Goldsmith CS, Zaki SR, et al. A reassortant bunyavirus isolated from acute hemorrhagic fever cases in Kenya and Somalia. Virology. 2001;291:185–90. 10.1006/viro.2001.1201. [DOI] [PubMed] [Google Scholar]
- 22.Goller KV, Höper D, Schirrmeier H, Mettenleiter TC, Beer M. Schmallenberg virus as possible ancestor of Shamonda virus. Emerg Infect Dis. 2012;18:1644–6. 10.3201/eid1810.120835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Beer M, Conraths FJ, van der Poel WHM. Schmallenberg virus’—a novel orthobunyavirus emerging in Europe. Epidemiol Infect. 2013;141:1–8. 10.1017/S0950268812002245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Touré CT, Dieng I, Sankhe S, Kane M, Dia M, Mhamadi M, et al. Genomic characterization of a Bataï orthobunyavirus, previously classified as Ilesha virus, from field-caught mosquitoes in Senegal, Bandia 1969. Viruses. 2024;16:261. 10.3390/v16020261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Li P, Zhao D, Fu J, Zhang Y, Cai S, Deng M, et al. Orthobunyaviruses: epidemiology, innate immune escape, and intervention strategies. Virulence. 2025;16:2585624. 10.1080/21505594.2025.2585624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.De Regge N, Akabane. Aino and Schmallenberg virus: where do we stand and what do we know about the role of domestic ruminant hosts and Culicoides vectors in virus transmission and overwintering? Curr Opin Virol. 2017;27:15–30. 10.1016/j.coviro.2017.10.004. [DOI] [PubMed] [Google Scholar]
- 27.Matthews E, Chauhan L, Piquet AL, Tyler KL, Pastula DM. An overview of La Crosse virus disease. Neurohospitalist. 2022;12:587–8. 10.1177/19418744221077738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Viglietta M, Bellone R, Blisnick AA, Failloux AB. Vector specificity of arbovirus transmission. Front Microbiol. 2021;12:773211. 10.3389/fmicb.2021.773211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Coleman KJ, Chauhan L, Piquet AL, Tyler KL, Pastula DM. An overview of Jamestown Canyon virus disease. Neurohospitalist. 2021;11:277–8. 10.1177/19418744211005948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gibbens N. Schmallenberg virus: a novel viral disease in northern Europe. Vet Rec. 2012;170:58. 10.1136/vr.e292. [DOI] [PubMed] [Google Scholar]
- 31.Rocklöv J, Dubrow R. Climate change: an enduring challenge for vector-borne disease prevention and control. Nat Immunol. 2020;21:479–83. 10.1038/s41590-020-0648-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Morrison A, White JL, Hughes HR, et al. Oropouche virus disease among U.S. travelers—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73:769–73. 10.15585/mmwr.mm7335e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Centers for Disease Control and Prevention. Clinical overview of Oropouche virus disease. Updated 19. November 2025. https://www.cdc.gov/oropouche/hcp/clinical-overview/index.html. Accessed 16 July 2026.
- 34.Pan American Health Organization/World Health Organization. Epidemiological update: Oropouche in the Region of the Americas, 13. August 2025. https://www.paho.org/en/documents/epidemiological-update-oropouche-region-americas-13-august-2025. Accessed 16 July 2026.
- 35.Ekström E, Kaansalo K, Suvanto MT, Utriainen M, Putkuri N, Vapalahti O, et al. Detection of California serogroup orthobunyavirus antibodies and Inkoo virus RNA in patients, Finland. Epidemiol Infect. 2025;153:e83. 10.1017/S0950268825100289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Woods TA, Johnson SF, Evans AB, Peterson KE. Neutralizing antibodies against California serogroup orthobunyaviruses in human serum samples, Montana, USA. Emerg Infect Dis. 2025;31:699–709. 10.3201/eid3104.241520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Vahey GM, Lindsey NP, Staples JE, Hills SL. La Crosse virus disease in the United States, 2003–2019. Am J Trop Med Hyg. 2021;105:807–12. 10.4269/ajtmh.21-0294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Centers for Disease Control and Prevention. Data and maps for Jamestown Canyon virus. Updated 3 June 2026. https://www.cdc.gov/jamestown-canyon/data-maps/index.html. Accessed 16 July 2026.
- 39.Centers for Disease Control and Prevention. Historic data (2011–2025): Jamestown Canyon virus. Updated 3 June 2026. https://www.cdc.gov/jamestown-canyon/data-maps/historic-data.html. Accessed 16 July 2026.
- 40.Lwande OW, Bucht G, Ahlm C, Ahlm K, Näslund J, Evander M. Mosquito-borne Inkoo virus in northern Sweden: isolation and whole-genome sequencing. Virol J. 2017;14:61. 10.1186/s12985-017-0725-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Hartman AL, Myler PJ. Bunyavirales: scientific gaps and prototype pathogens for a large and diverse group of zoonotic viruses. J Infect Dis. 2023;228(Suppl 6):S376–89. 10.1093/infdis/jiac338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Centers for Disease Control and Prevention. Clinical testing and diagnosis for Jamestown Canyon virus disease. Updated 19 November 2025. https://www.cdc.gov/jamestown-canyon/hcp/diagnosis-testing/index.html. Accessed 16 July 2026.
- 43.Centers for Disease Control and Prevention. Jamestown Canyon virus diagnostic testing algorithm. 21. August 2024. https://www.cdc.gov/jamestown-canyon/media/pdfs/2024/09/Jamestown-Canyon-Virus-Diagnostic-Algorithm.pdf. Accessed 16 July 2026.
- 44.Evans AB, Peterson KE. Cross-reactivity of neutralizing antibodies to the encephalitic California serogroup orthobunyaviruses varies by virus and genetic relatedness. Sci Rep. 2021;11:16424. 10.1038/s41598-021-95757-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Rodriguez-Morales AJ, Sah R, Silva-Ramos CR, Pava-Garzón DM. Challenges in emerging and reemerging arboviral diseases: the examples of Oropouche and yellow fever. Pathogens. 2025;14:621. 10.3390/pathogens14070621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.O’Connor TW, Hick PM, Finlaison DS, Kirkland PD, Toribio JALML. Revisiting the importance of orthobunyaviruses for animal health: a scoping review of livestock disease, diagnostic tests, and surveillance strategies for the Simbu serogroup. Viruses. 2024;16:294. 10.3390/v16020294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Bilk S, Schulze C, Fischer M, Beer M, Hlinak A, Hoffmann B. Organ distribution of Schmallenberg virus RNA in malformed newborns. Vet Microbiol. 2012;159:236–8. 10.1016/j.vetmic.2012.03.035. [DOI] [PubMed] [Google Scholar]
- 48.Wernike K, Aebischer A, Sick F, Szillat KP, Beer M. Differentiation of antibodies against selected Simbu serogroup viruses by a glycoprotein Gc-based triplex ELISA. Vet Sci. 2021;8:12. 10.3390/vetsci8010012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Bréard E, Lara E, Comtet L, Viarouge C, Doceul V, Desprat A, et al. Validation of a commercially available indirect ELISA using a nucleocapsid recombinant protein for detection of Schmallenberg virus antibodies. PLoS ONE. 2013;8:e53426. 10.1371/journal.pone.0053426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019;20:341–55. 10.1038/s41576-019-0113-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Briese T, Kapoor A, Mishra N, Jain K, Kumar A, Jabado OJ, Lipkin WI. Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis. mBio. 2015;6:e01491–15. 10.1128/mBio.01491-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Rodriguez C, Gricourt G, Ndebi M, Demontant V, Poiteau L, Burrel S, et al. Fatal encephalitis caused by Cristoli virus, an emerging orthobunyavirus, France. Emerg Infect Dis. 2020;26:1287–90. 10.3201/eid2606.191431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Pastula DM, Hoang Johnson DK, White JL, Dupuis AP, Fischer M, Staples JE. Jamestown Canyon virus disease in the United States, 2000–2013. Am J Trop Med Hyg. 2015;93:384–9. 10.4269/ajtmh.15-0196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Kapuscinski ML, Bergren NA, Russell BJ, Lee JS, Borland EM, Hartman DA, et al. Genomic characterization of 99 viruses from the bunyavirus families Nairoviridae, Peribunyaviridae, and Phenuiviridae, including 35 previously unsequenced viruses. PLoS Pathog. 2021;17:e1009315. 10.1371/journal.ppat.1009315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Foster JE, López K, Eastwood G, Guzman H, Carrington CVF, Tesh RB, et al. Phylogenetic characterization of orthobunyaviruses isolated from Trinidad shows evidence of natural reassortment. Virus Genes. 2023;59:473–8. 10.1007/s11262-023-01973-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Heitmann A, Gusmag F, Rathjens MG, Maurer M, Frankze K, Schicht S, et al. Mammals preferred: reassortment of Batai and Bunyamwera orthobunyavirus occurs in mammalian but not insect cells. Viruses. 2021;13:1702. 10.3390/v13091702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Bowen JM, Gunter K, Lunel AM, Omoga DCA, Jones JE, Giesel H, et al. Probing orthobunyavirus reassortment using Bunyamwera and Batai viruses as models. PLoS Negl Trop Dis. 2025;19:e0013120. 10.1371/journal.pntd.0013120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, et al. Taxonomy of the order Bunyavirales: update 2019. Arch Virol. 2019;164:1949–65. 10.1007/s00705-019-04253-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Marklewitz M, Junglen S. Evolutionary and ecological insights into the emergence of arthropod-borne viruses. Acta Trop. 2019;190:52–8. 10.1016/j.actatropica.2018.10.006. [DOI] [PubMed] [Google Scholar]
- 60.Szemiel AM, Willett BJ. St. Abb’s Head phlebovirus: a separate virus species or a strain of Uukuniemi phlebovirus? Access Microbiol. 2019;1:675. 10.1099/acmi.ac2019.po0420. [DOI] [Google Scholar]
- 61.Hughes HR, Adkins S, Alkhovskiy S, Beer M, Blair C, Calisher CH, et al. ICTV virus taxonomy profile: Peribunyaviridae. J Gen Virol. 2020;101:1–2. 10.1099/jgv.0.001365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Patiño L, Benítez AD, Carrazco-Montalvo A, Regato-Arrata M. Genomics for arbovirus surveillance: considerations for routine use in public health laboratories. Viruses. 2024;16:1242. 10.3390/v16081242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Wernike K, Beer M. Schmallenberg virus: to vaccinate, or not to vaccinate? Vaccines (Basel). 2020;8:287. 10.3390/vaccines8020287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Destoumieux-Garzón D, Mavingui P, Boetsch G, Boissier J, Darriet F, Duboz P, et al. The One Health concept: 10 years old and a long road ahead. Front Vet Sci. 2018;5:14. 10.3389/fvets.2018.00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
No datasets were generated or analysed during the current study.
